CN114366741A - 新方法 - Google Patents

新方法 Download PDF

Info

Publication number
CN114366741A
CN114366741A CN202210062907.5A CN202210062907A CN114366741A CN 114366741 A CN114366741 A CN 114366741A CN 202210062907 A CN202210062907 A CN 202210062907A CN 114366741 A CN114366741 A CN 114366741A
Authority
CN
China
Prior art keywords
compound
formula
use according
effective amount
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210062907.5A
Other languages
English (en)
Chinese (zh)
Inventor
K·瓦诺维尔
李鹏
S·梅特斯
R·戴维斯
L·P·文诺格勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53274093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN114366741(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CN114366741A publication Critical patent/CN114366741A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
CN202210062907.5A 2013-12-03 2014-12-03 新方法 Pending CN114366741A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201361911416P 2013-12-03 2013-12-03
US61/911,416 2013-12-03
US201461925607P 2014-01-09 2014-01-09
US61/925,607 2014-01-09
US201461975702P 2014-04-04 2014-04-04
US61/975,702 2014-04-04
US201462032326P 2014-08-01 2014-08-01
US62/032,326 2014-08-01
PCT/US2014/068443 WO2015085004A1 (en) 2013-12-03 2014-12-03 Novel methods
CN201480074647.7A CN105939712A (zh) 2013-12-03 2014-12-03 新方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480074647.7A Division CN105939712A (zh) 2013-12-03 2014-12-03 新方法

Publications (1)

Publication Number Publication Date
CN114366741A true CN114366741A (zh) 2022-04-19

Family

ID=53274093

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210062907.5A Pending CN114366741A (zh) 2013-12-03 2014-12-03 新方法
CN201480074647.7A Pending CN105939712A (zh) 2013-12-03 2014-12-03 新方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480074647.7A Pending CN105939712A (zh) 2013-12-03 2014-12-03 新方法

Country Status (17)

Country Link
US (7) US9956227B2 (US07928230-20110419-C00107.png)
EP (2) EP3076967B1 (US07928230-20110419-C00107.png)
JP (4) JP6475727B2 (US07928230-20110419-C00107.png)
KR (8) KR102495941B1 (US07928230-20110419-C00107.png)
CN (2) CN114366741A (US07928230-20110419-C00107.png)
AU (4) AU2014360452C1 (US07928230-20110419-C00107.png)
BR (1) BR112016012781A2 (US07928230-20110419-C00107.png)
CA (4) CA2932610C (US07928230-20110419-C00107.png)
DK (1) DK3076967T3 (US07928230-20110419-C00107.png)
ES (1) ES2893621T3 (US07928230-20110419-C00107.png)
HU (1) HUE056496T2 (US07928230-20110419-C00107.png)
IL (3) IL305990A (US07928230-20110419-C00107.png)
MX (3) MX2016007219A (US07928230-20110419-C00107.png)
PL (1) PL3076967T3 (US07928230-20110419-C00107.png)
PT (1) PT3076967T (US07928230-20110419-C00107.png)
RU (1) RU2682658C1 (US07928230-20110419-C00107.png)
WO (1) WO2015085004A1 (US07928230-20110419-C00107.png)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102372149B1 (ko) 2007-03-12 2022-03-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
USRE48839E1 (en) * 2008-05-27 2021-12-07 Intra-Cellular Therapies, Inc Methods and compositions for sleep disorders and other disorders
PT2364142T (pt) 2008-10-28 2018-04-23 Arena Pharm Inc Composições de um modulador do recetor da serotonina 5-ht2a para o tratamento de distúrbios com ele relacionados
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
WO2013155506A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel compositions and methods
EP2968320B1 (en) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organic compounds
KR102495941B1 (ko) 2013-12-03 2023-02-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
PT3125893T (pt) 2014-04-04 2023-11-21 Intra Cellular Therapies Inc Gama-carbolinas fusionadas com heterociclo deuterado como antagonistas de recetores 5-ht2a
MX2016013046A (es) 2014-04-04 2017-02-15 Intra Cellular Therapies Inc Compuestos organicos.
PL3261645T3 (pl) 2015-02-27 2021-12-06 Dechra Limited Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów
KR20180064373A (ko) * 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
CN105560192A (zh) * 2016-01-07 2016-05-11 万全万特制药江苏有限公司 一种棕榈酸帕利哌酮长效微球注射液的制备方法
KR20180099905A (ko) 2016-01-26 2018-09-05 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CA3016706A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
IL297676B2 (en) 2016-03-25 2023-12-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
JP2019510039A (ja) * 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規塩類および結晶
JP6997718B2 (ja) * 2016-03-28 2022-01-18 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規共結晶
EP3525763A4 (en) 2016-10-12 2020-06-17 Intra-Cellular Therapies, Inc. AMORPHE FIXED DISPERSIONS
WO2018102673A1 (en) * 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018175969A1 (en) * 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
WO2019023063A1 (en) * 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
IL272249B2 (en) 2017-07-26 2023-11-01 Intra Cellular Therapies Inc organic compounds
US11440911B2 (en) 2017-09-26 2022-09-13 Intra-Cellular Therapies, Inc. Salts and crystals
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
KR102089737B1 (ko) 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
MX2020009668A (es) 2018-03-16 2021-01-08 Intra Cellular Therapies Inc Métodos novedosos.
CA3102948A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
WO2019241278A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
CN112585690A (zh) 2018-06-21 2021-03-30 阿奎斯蒂弗医疗股份有限公司 用于制作含有药物活性物质的个性化个体单位剂量的系统和方法
BR112021003838A2 (pt) * 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
EP3843738A4 (en) * 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. NEW METHODS
CA3110997A1 (en) 2018-09-07 2020-03-12 Aquestive Therapeutics, Inc. Oral film compositions and dosage forms having precise active dissolution profiles
KR20200087594A (ko) 2019-01-11 2020-07-21 한국화학연구원 레티노익산을 포함하는 미립구형 서방출 제제 및 그의 제조방법
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CA3141223A1 (en) 2019-07-07 2021-01-14 Sharon Mates Novel methods
CA3159382A1 (en) 2019-11-01 2021-05-06 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
KR20220126287A (ko) 2019-11-14 2022-09-15 어퀘스티브 테라퓨틱스, 아이엔씨. 멀티모달 조성물 및 치료 방법
US11753419B2 (en) 2019-12-11 2023-09-12 Intra-Cellular Therapies, Inc. 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
US11344503B2 (en) * 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
KR102383448B1 (ko) 2020-04-20 2022-04-06 한국화학연구원 락트산 또는 글리콜산을 포함하는 미립구형 서방출 제제 및 그의 제조방법
JP2024505429A (ja) 2021-01-15 2024-02-06 アクエスティブ セラピューティクス インコーポレイテッド プロドラッグ組成物及び治療の方法
MX2023009754A (es) 2021-02-24 2023-08-30 Oakwood Laboratories LLC Formulaciones de microesferas que comprenden lurasidona y metodos para fabricar y usar las mismas.
WO2022192476A1 (en) 2021-03-09 2022-09-15 Aquestive Therapeutics, Inc. Dosage forms having equivalent biocomparable profiles
KR20240132476A (ko) * 2022-01-03 2024-09-03 엔그레일 테라퓨틱스, 인크. 중수소화 유기 화합물 및 이의 용도
US20230372336A1 (en) 2022-05-18 2023-11-23 Intra-Cellular Therapies, Inc. Novel methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105059A (zh) * 2008-05-27 2011-06-22 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
CN103209704A (zh) * 2010-04-22 2013-07-17 细胞内治疗公司 有机化合物

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US3914421A (en) * 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
IE41352B1 (en) 1974-04-01 1979-12-19 Pfizer 5-aryl-1,2,3,4-tetrahydro- -carbolines
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
ZA871987B (en) 1986-03-19 1988-05-25 Kumiai Chemical Industry Co 5h-1,3,4-thiadiazole(3,2-a)pyrimidin-5-one derivatives and fungicidal compositions containing the same
ATE91129T1 (de) 1986-04-07 1993-07-15 Kumiai Chemical Industry Co 5h-1,3,4-thiadiazolo(3,2-a>pyrimidin-5-onderivate und diese enthaltende gartenbau- und landwirtschaftliche fungizidmittel.
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
IT1271352B (it) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
ES2236700T3 (es) 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
US6884429B2 (en) 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6395939B1 (en) 1997-10-06 2002-05-28 Massachusetts Institute Of Technology Diaryl ether condensation reactions
US6235936B1 (en) * 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
CA2322194C (en) 1998-02-26 2011-04-26 Massachusetts Institute Of Technology Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
CA2336691C (en) 1998-07-10 2009-02-10 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
CA2354472C (en) 1998-12-17 2009-02-24 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
NO309305B1 (no) 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
ES2223536T3 (es) 1999-06-15 2005-03-01 Bristol-Myers Squibb Pharma Company Gamma-carbolinas condensadas con heterociclos sustituidas.
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
MXPA03005438A (es) 2000-12-20 2004-05-05 Bristol Myers Squibb Co Pirioindoles substituidos como agonistas y antagonistas de serotonina.
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
DK2272813T3 (en) 2001-04-24 2017-02-27 Massachusetts Inst Of Tech (Mit) COPPER CATALYST CREATION OF CARBON OXYGEN COMPOUNDS
DE10123129A1 (de) 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
JP2005526691A (ja) 2001-08-08 2005-09-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 治療剤１Ｈ−ピリド［４，３−ｂ］インドール
EP1314554A1 (fr) 2001-11-23 2003-05-28 Kba-Giori S.A. Dispositif de décollage d'éléments de sécurité
DE10162121A1 (de) 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
KR100699516B1 (ko) 2002-07-29 2007-03-26 알자 코포레이션 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004013094A2 (en) 2002-08-02 2004-02-12 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004041281A1 (en) 2002-11-01 2004-05-21 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
JP4486505B2 (ja) 2002-12-19 2010-06-23 ブリストル−マイヤーズ スクイブ カンパニー セロトニン・レセプタ作用薬および拮抗薬としての置換トリ環式ガンマ−カルボリン化合物
WO2004064738A2 (en) * 2003-01-16 2004-08-05 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
DE602004017325D1 (de) 2003-07-21 2008-12-04 Smithkline Beecham Corp (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl)-l-phenylalanylü-2-pyrrolidincarbonitril-p-toluolsulfonsäuresalz und wasserfreie kristalline formen davon
SA04250304B1 (ar) 2003-09-26 2009-03-11 سولفاي فارماسوتيكالز بي . في مشتقات هكسا - واوكتاهيدرو - بيريدو {1،2-a} بيرازين ذات نشاط مضاد لـ nk1
JP2005259113A (ja) 2004-02-12 2005-09-22 Ricoh Co Ltd プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
CA2564018A1 (en) 2004-03-05 2005-10-13 Pharma C S.A. 8-phenoxy-.gamma. carboline derivatives
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
ATE506945T1 (de) 2004-09-20 2011-05-15 Sinai School Medicine Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität
CA2581023A1 (en) 2004-09-21 2006-03-30 Pfizer Products Inc. N-methyl hydroxyethylamine useful in treating cns conditions
US7614727B2 (en) 2004-09-30 2009-11-10 Fujifilm Corporation Liquid ejection head, manufacturing method thereof, and image forming apparatus
AU2005315914B2 (en) 2004-12-15 2011-03-03 F. Hoffmann-La Roche Ag Bi- and tricyclic substituted phenyl methanones as glycine transporter I (GlyT-1) inhibitors for the treatment of Alzheimer's disease
ZA200707010B (en) 2005-01-25 2009-01-28 Celgene Corp Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidini-3-yl)-isoindole-1-3-dione
EP1856075A1 (en) 2005-01-25 2007-11-21 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
WO2006123359A2 (en) * 2005-03-01 2006-11-23 Sun Pharmaceutical Industries Limited A process of making microspheres
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP1973876A2 (en) 2006-01-13 2008-10-01 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
KR102372149B1 (ko) 2007-03-12 2022-03-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
BRPI0815850A2 (pt) 2007-08-01 2014-10-07 Medivation Neurology Inc "método para tratar, retardar a progressão, prevenir ou atrasar o desenvolvimento de esquizofrenia em um individuo, composiçã farmaceuticamente aceitável, kit e método para reforçar uma resposta de um individuo a um antipsicótico"
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
US20090209608A1 (en) 2007-08-29 2009-08-20 Protia, Llc Deuterium-enriched asenapine
US20090076159A1 (en) 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched eplivanserin
AU2009212065B2 (en) 2008-02-05 2014-03-20 Clera Inc. Compositions and methods for alleviating depression or improving cognition
AR070346A1 (es) 2008-02-07 2010-03-31 Schering Corp Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
SI2262505T1 (sl) 2008-03-12 2015-03-31 Intra-Cellular Therapies, Inc. Substituirana heterociklirano zliti gama-karbolinska trdna snov
US8309772B2 (en) 2008-07-31 2012-11-13 Celanese International Corporation Tunable catalyst gas phase hydrogenation of carboxylic acids
WO2010037142A1 (en) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US20100159033A1 (en) 2008-09-29 2010-06-24 Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
CN102421418A (zh) * 2009-03-09 2012-04-18 得克萨斯系统大学评议会 在药物递送中有用的中空金纳米球（HAuNSs）和装载HAuNSs的微球体
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
WO2013155506A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel compositions and methods
AR092568A1 (es) 2012-09-14 2015-04-22 Abbvie Deutschland Derivados triciclicos de quinolinas y de quinoxalinas
EP2968320B1 (en) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organic compounds
KR102495941B1 (ko) * 2013-12-03 2023-02-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
MX2016013046A (es) 2014-04-04 2017-02-15 Intra Cellular Therapies Inc Compuestos organicos.
PT3125893T (pt) * 2014-04-04 2023-11-21 Intra Cellular Therapies Inc Gama-carbolinas fusionadas com heterociclo deuterado como antagonistas de recetores 5-ht2a
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
KR20180014778A (ko) 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 제형 및 이의 용도
KR20180099905A (ko) 2016-01-26 2018-09-05 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2017165755A1 (en) 2016-03-25 2017-09-28 Intra-Cellular Therapies, Inc. Organic compounds
IL297676B2 (en) * 2016-03-25 2023-12-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
JP6997718B2 (ja) * 2016-03-28 2022-01-18 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規共結晶
WO2018106916A1 (en) 2016-12-07 2018-06-14 Concert Pharmaceuticals, Inc. Deuterated quinoxaline compounds
WO2018175969A1 (en) * 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
EP3717484A4 (en) 2017-11-27 2021-08-04 Egis Gyógyszergyár Zrt. PROCESS FOR THE PRODUCTION OF LUMATEPERON AND ITS SALT
US11839614B2 (en) * 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
MX2020009668A (es) * 2018-03-16 2021-01-08 Intra Cellular Therapies Inc Métodos novedosos.
US20210009592A1 (en) * 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
US20210315891A1 (en) * 2018-08-29 2021-10-14 Intra-Cellular Therapies, Inc. Novel compositions and methods
US20220362241A1 (en) * 2019-09-25 2022-11-17 Intra-Cellular Therapies, Inc. Novel methods
US20230372336A1 (en) * 2022-05-18 2023-11-23 Intra-Cellular Therapies, Inc. Novel methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105059A (zh) * 2008-05-27 2011-06-22 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
CN103209704A (zh) * 2010-04-22 2013-07-17 细胞内治疗公司 有机化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Study of a novel antipsychotic ITI-007 in schizophrenia", 《CLINICALTRAILS.GOV》 *
KIMBERLY VANOVER等: "ITI-007: a novel therapy for the treatment of schizophrenia and related psychoses", 《INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY》 *

Also Published As

Publication number Publication date
CA3148326A1 (en) 2015-06-11
US20160310502A1 (en) 2016-10-27
CA3148303C (en) 2024-02-27
RU2682658C1 (ru) 2019-03-20
KR20210049200A (ko) 2021-05-04
CA2932610C (en) 2023-08-22
US10322134B2 (en) 2019-06-18
US10960010B2 (en) 2021-03-30
KR102373288B1 (ko) 2022-03-10
US20190298730A1 (en) 2019-10-03
JP2016539144A (ja) 2016-12-15
IL246002B (en) 2022-07-01
US20240024334A1 (en) 2024-01-25
MX2016007219A (es) 2016-09-16
US20190290655A1 (en) 2019-09-26
CN105939712A (zh) 2016-09-14
AU2019200301A1 (en) 2019-02-07
WO2015085004A1 (en) 2015-06-11
US11026951B2 (en) 2021-06-08
AU2014360452C1 (en) 2019-05-16
US10960009B2 (en) 2021-03-30
IL305990A (en) 2023-11-01
DK3076967T3 (da) 2021-10-25
KR20230023817A (ko) 2023-02-17
JP2019077724A (ja) 2019-05-23
JP2021075566A (ja) 2021-05-20
US20190328745A1 (en) 2019-10-31
ES2893621T3 (es) 2022-02-09
PL3076967T3 (pl) 2021-12-20
AU2014360452A1 (en) 2016-07-21
KR20240119197A (ko) 2024-08-06
KR20220103822A (ko) 2022-07-22
BR112016012781A2 (pt) 2017-08-08
KR102372145B1 (ko) 2022-03-07
JP2023089113A (ja) 2023-06-27
JP7262495B2 (ja) 2023-04-21
JP6475727B2 (ja) 2019-02-27
AU2019200301B2 (en) 2020-01-30
KR20160093055A (ko) 2016-08-05
IL246002A0 (en) 2016-07-31
IL293523B1 (en) 2023-10-01
KR20230058736A (ko) 2023-05-03
KR20210101326A (ko) 2021-08-18
KR102287288B1 (ko) 2021-08-06
CA3148303A1 (en) 2015-06-11
MX2022011140A (es) 2022-10-13
KR102421656B1 (ko) 2022-07-15
CA3205777A1 (en) 2015-06-11
US9956227B2 (en) 2018-05-01
EP3076967A4 (en) 2017-05-10
MX2021007665A (es) 2022-09-09
EP3076967A1 (en) 2016-10-12
JP6874028B2 (ja) 2021-05-19
KR102495941B1 (ko) 2023-02-06
PT3076967T (pt) 2021-10-07
EP3076967B1 (en) 2021-07-28
CA2932610A1 (en) 2015-06-11
HUE056496T2 (hu) 2022-02-28
IL293523B2 (en) 2024-02-01
AU2020202386B2 (en) 2021-09-30
US20180200256A1 (en) 2018-07-19
KR20210049199A (ko) 2021-05-04
AU2020202386C1 (en) 2022-04-07
US20210322433A1 (en) 2021-10-21
KR102692169B1 (ko) 2024-08-05
EP3666271A1 (en) 2020-06-17
IL293523A (en) 2022-08-01
AU2014360452B2 (en) 2018-10-18
AU2020202386A1 (en) 2020-04-30
AU2021290277B2 (en) 2023-07-20
AU2021290277A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
US10960010B2 (en) Pharmaceutical compositions for sustained or delayed release

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination